Tfh/Tfr Ratio in IgA Nephropathy Patients

Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy

Recruiting N/A Interventional Study
Glomerulonephritis, IGA
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
75 (estimated)
Sponsor
Centre Hospitalier Universitaire de Besancon · Other
Who this trial is looking for

This trial is looking for patients with IgA nephropathy to understand how certain immune cells relate to disease progression. Participants will be grouped based on their condition and monitored over time to see how it changes.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with IgA nephropathy confirmed by a kidney biopsy
  • I have had my kidney condition for at least 5 years
  • I was diagnosed from 2009 onwards
  • I am part of a control group with lupus, ANCA-associated vasculitis, or polycystic kidney disease
  • I have at least 8 functional glomeruli

You may not be able to join if

  • I have legal incapacity or limited legal capacity
  • I have no social security coverage
  • I am pregnant or not using an effective contraceptive method

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study aims to investigate the relevance of the Tfh/Tfr (Follicular helper T cells/ Follicular regulatory T cells) ratio in patients with IgA nephropathy: * To identify a differential expression of the Tfh/Tfr ratio in patients considered stable or progressive * To predict, at diagnosis, the clinical evolution of the disease (progressive or stable form) in the first year.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * IgA nephropathy histologically proven on renal biopsy according to KDIGO criteria, with 8 permeable glomeruli (patients diagnosed from 2009 with a minimum follow-up for their nephropathy of 5 years (arm 1) or patients diagnosed during the study (arm 2)) Control patients: Lupu…
Contacts

Charline Vauchy, PhD.

0381218875

cvauchy@chu-besancon.fr

CONTACT